Update SWENOTECA X

A revision of the SWENOTECA X protocol and new patients information have now been published. The main change is regarding stage I seminoma patients with risk factors (stromal invation in rete testis or/and tumor over 4 cm). For this patient group surveillance or adjuvant carboplatin are now equal options following orchiectomy. This is a change from earlier versions of SWENOTECA X, where adjuvant carboplatin was recommended to patients with risk factors. For patients without risk factors surveillance is still the standard option.